Our client seeks to identify technologies and products for in-licensing with regional exclusivity in Russia, CIS, and Global Markets.

The company is a fast growing, Swiss-headquartered pharmaceutical group of companies focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to facilitate patient access to medicines across the unlicensed and licensed product phases.

Russia/CIS Region Focus Areas:

Full commercial representation of the technology/product in Russia and CIS region (including Ukraine and Baltics)

Various market access routes available including Named Patient Sales and an application for Market Authorization (MA), to be determined on a product basis

Priorities:

  • Innovative Products with therapeutic value
  • Inpatient Products preferred, but also open to Outpatient
  • Focus on Pharmaceuticals, but innovative Medical Devices could also be of interest

Indications / Areas / Products of Interest include:

  • Oncology
  • Dermatology
  • Orphan Disease (Diabetes)
  • Cardiovascular (Myocardial Infarction)
  • Hospital Products (Antibiotics / Septic Shock)
  • Neurology (Multiple Sclerosis / Parkinson’s Disease)

Excluded Technology Areas include:

  • Generics
  • Alzheimer’s Disease

Desired Level of Development:

  • Approved / Marketed products – U.S. FDA and/or EU approved products are preferred
  • Pre-registration products
  • Phase 3 acceptable

Global Markets Focus Areas:

Therapeutics available through Managed Access Program (MAP)

Therapeutics available through Named Patient Access Program (NPP) transitioning to MA for Switzerland

Priority:  Innovative Products with an unmet patient need

Indications / Areas / Products of Interest include:

  • Oncology
  • Orphan Diseases
  • Any other disease areas with unmet patient needs

Excluded Technology Areas Include:

  • Generics
  • Biosimilars
  • OTCs

Desired level of development:

  • Approved / Marketed products – at least in one major market (irrespectively which one)
  • Pre-registration products (Companies with commercial approach in place)

­